Article tools
Author information

Research Article

Biphasic forearm vascular responses to intraarterial arginine vasopressin.

S Suzuki, A Takeshita, T Imaizumi, Y Hirooka, M Yoshida, S Ando and M Nakamura

Research Institute of Angiocardiology and Cardiovascular Clinic, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

Published August, 1989

Forearm vascular responses to arginine vasopressin (AVP) infused into a brachial artery in a wide range of infusion rates (0.05-2.0 ng/kg per min) were examined in 20 young healthy volunteers. Intraarterial AVP at lower doses (0.05 and 0.1 ng/kg per min) caused forearm vasoconstriction, whereas AVP at a dose of 0.2 ng/kg per min or higher caused forearm vasodilatation. The maximal forearm vasoconstriction was induced at the venous plasma AVP level of 76.3 +/- 8.8 pg/ml. Forearm vasodilatation was associated with the venous plasma AVP level of 369 +/- 43 pg/ml or higher. Forearm vasodilatation was the result of the direct effect of AVP since forearm blood flow and vascular resistance in the contralateral arm did not change. We attempted to explore the mechanisms involved in AVP-induced direct vasodilatation. The treatment with indomethacin, 75 mg/d for 3 d, did not alter AVP-induced forearm vasodilatation. In contrast, intraarterial infusion of isoosmolar CaCl2 totally prevented AVP-induced forearm vasodilatation. Intra-arterial CaCl2 also markedly attenuated forearm vasodilatation induced by intraarterial sodium nitroprusside, but did not alter forearm vasodilatation induced by intraarterial isoproterenol. These results indicate that the direct vascular effects of intra-arterial AVP on the forearm vessels are biphasic, causing vasoconstriction at lower doses and vasodilatation at higher doses. The direct vasodilatation induced by intraarterial AVP at higher doses is not mediated by prostaglandins but may involve cGMP-related mechanisms.

Browse pages

Click on an image below to see the page. View PDF of the complete article

Articles that cite
this article:

Abnormal pressor response to vasopressin in patients with cirrhosis: Evidence for impaired buffering mechanisms
Richard Moreau, Antoine Hadengue, Thierry Soupison, Guy Mechin, Michel Assous, Jacqueline Roche-sicot, Christian Sicot
Hepatol 12(1):7. [CrossRef]

Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP)
J. E. Kaufmann, U. M. Vischer
J Thromb Haemost 1(4):682. [CrossRef]

Desmopressin (DDAVP) induces NO production in human endothelial cells via V2 receptor- and cAMP-mediated signaling
J. E. Kaufmann, M. Iezzi, U. M. Vischer
J Thromb Haemost 1(4):821. [CrossRef]


Masayuki Tanahashi, Toshihiro Sekizawa, Makoto Yoshida, Mizue Suzuki-kusaba, Hiroaki Hisa, Susumu Satoh
J Cardiovasc Pharmacol 33(3):401. [CrossRef]

Vasodilation induced by vasopressin V2 receptor stimulation in afferent arterioles
Toshiaki Tamaki, Kayo Kiyomoto, Hong He, Atsufumi Tomohiro, Akira Nishiyama, Yasuharu Aki, Shoji Kimura, Youichi Abe
Kidney Int 49(3):722. [CrossRef]

Vascular Effects of RWJ-676070, a Selective Combined V1a/V2 Vasopressin Receptor Antagonist
L Coltamai, M Bucher, MP Maillard, U Shukla, N Bohidar, L Haskell, K Bertelsen, M Fedgchin, B Vogt, M Burnier
Clin Pharmacol Ther 85(2):145. [CrossRef]

Dilatation by angiotensin II of the rat femoral arterial bed in vivo via pressure/flow-induced release of nitric oxide and prostaglandins
Akos Heinemann, Christof H. Wachter, Bernhard A. Peskar, Peter Holzer
Br J Pharmacol 122(6):975. [CrossRef]